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sistance with personal crisis management, and facilitation 
of early intervention. SUMMIT-PERSON additionally offered 
regular expert chats. The primary outcome was ‘well weeks’, 
i.e. weeks with at most mild symptoms assessed by the Lon-
gitudinal Interval Follow-Up Evaluation, during 24 months 
after the index treatment.  Results: SUMMIT compared to 
TAU reduced the time with an unwell status (OR 0.48; 95% 
CI 0.23–0.98) through faster transitions from unwell to well 
(OR 1.44; 95% CI 0.83–2.50) and slower transitions from well 
to unwell (OR 0.69; 95% CI 0.44–1.09). Contrary to the hy-
pothesis, SUMMIT-PERSON was not superior to either SUM-
MIT (OR 0.77; 95% CI 0.38–1.56) or TAU (OR 0.62; 95% CI 
0.31–1.24). The efficacy of SUMMIT was strongest 8 months 
after the intervention.  Conclusions: The fully automated In-
ternet-delivered augmentation strategy SUMMIT has the 
potential to improve TAU by reducing the lifelong burden 
of patients with recurrent depression. The fact that the ef-
fects wear off suggests a time-unlimited extension. 
 © 2016 S. Karger AG, Basel 
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 Abstract 
 Background: Strategies to improve the life of patients suf-
fering from recurrent major depression have a high rele-
vance. This study examined the efficacy of 2 Internet-deliv-
ered augmentation strategies that aim to prolong symp-
tom-free intervals.  Methods: Efficacy was tested in a 3-arm, 
multicenter, open-label, evaluator-blind, randomized con-
trolled trial. Upon discharge from inpatient mental health 
care, 232 adults with 3 or more major depressive episodes 
were randomized to 1 of 2 intervention groups (SUMMIT or 
SUMMIT-PERSON) or to treatment as usual (TAU) alone. 
Over 12 months, participants in both intervention arms re-
ceived, in addition to TAU, intense monitoring via e-mail or 
a smartphone, including signaling of upcoming crises, as-
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 Recurrent major depressive disorder (MDD) reduces 
the quality of life of the affected individuals, their families, 
and social networks and causes significant economic loss-
es for society  [1–4] . The lifetime risk of relapse or recur-
rence following a single episode is estimated at 70%, fur-
ther increasing with succeeding episodes  [5–7] . Relapse 
and recurrence are more likely if symptoms have not ful-
ly resolved during acute-phase treatment  [8, 9] .
 Maintenance pharmacotherapy has become a key ele-
ment in treatment guidelines  [10–15] . Time-limited 
continuation and maintenance phase psychotherapies 
also appear promising for relapse prevention  [16–24] . 
Specifically, continuation cognitive therapy and contin-
uation phase fluoxetine were shown to reduce relapse 
over 8 months significantly more than a pill placebo in 
adults who responded to acute-phase cognitive therapy 
and had an elevated risk of relapse due to slow or incom-
plete remission in acute-phase cognitive therapy. After 
discontinuation of the continuation phase treatments, 
the rates of relapse/recurrence no longer differed from 
the rate of the pill placebo group  [22] . Similarly, mainte-
nance cognitive-behavioral therapy reduced the 1-year 
follow-up relapse rate to 50%, compared to 73% for psy-
choeducation, in patients at a high risk for relapse due to 
more than 4 prior episodes  [23] . These studies exem-
plify the need for strategic extensions of evidence-based 
treatments  [25] . Although a considerable proportion of 
patients with recurrent depression may benefit, the ma-
jority will be confronted with a new episode. If they are 
not prepared for a possible negative course of their de-
pression, patients may attribute this development to 
their own failure, which may affect their coping efforts. 
Inter- and intraindividually varying courses of the illness 
underline the need for flexible, individualized, long-
term, and in many cases lifelong strategies  [26, 27] with 
the aim of prolonging interepisode intervals and reduc-
ing the severity as well as the duration of newly recurring 
episodes.
 Based on growing evidence that mental health services 
can be effectively delivered over the Internet  [28–35] , this 
project tested the efficacy of 2 versions of the individual-
ized, Internet-delivered augmentation strategy SUMMIT 
(Supportive Monitoring and Depression Management 
over the Internet) for patients with recurrent depression 
after acute-phase psychiatric treatment. We investigated 
whether these strategies in addition to treatment as usual 
(TAU) increase the ‘well time’ (i.e. absence of or at most 
mild depressive symptoms) in comparison to TAU alone 
during 24 months after the index treatment. Previous 
studies have suggested that personal guidance can both 
enhance outcomes and reduce attrition rates, which 
amount to up to 80% in unguided Internet interventions 
 [29, 35] . Therefore, this study investigated the specific ef-
fect of the option of consulting a clinical expert (SUM-
MIT-PERSON) compared to the fully automated Inter-
net-delivered intervention only (SUMMIT). Thus, this 
trial was designed to test the composed hypothesis of su-
periority of SUMMIT over TAU as well as of SUMMIT-
PERSON over SUMMIT.
 Stimulated by the finding that the preventive effects of 
continuation cognitive therapy and continuation phase 
fluoxetine weaken after discontinuation at about 8 
months in high-risk cognitive therapy responders  [22] , 
we additionally examined the efficacy of the new Inter-
net-delivered strategies 8 months after their termination, 
i.e. 20 months after the end of the index treatment.
 Methods 
 Details of the design and methods have been published else-
where  [36] ; the methods are briefly summarized here. This trial 
is registered in the German Clinical Trials Register (ID: 
DRKS00000435).
 Study Design 
 This trial is a multicenter, parallel-group, randomized con-
trolled trial with 2 intervention groups and 1 control group. Pa-
tients were recruited between June 2010 and March 2013 at 6 psy-
chiatric departments in Germany. Eligible patients were assigned 
to 12 months of participation in Internet-delivered augmentations 
of TAU either (a) with (SUMMIT-PERSON) or (b) without per-
sonal guidance (SUMMIT) or (c) with TAU alone. This study was 
conducted in accordance with Good Clinical Practice guidelines. 
A data safety and monitoring board was established and adverse 
events (AE) were documented. The Coordinating Center for Clin-
ical Trials of the University of Heidelberg provided independent 
study monitoring, the randomization list, and statistical analyses. 
The Ethics Committee of the Medical Faculty of the University of 
Heidelberg and the local Ethics Committees at the clinical sites ap-
proved the study protocol.
 Participants 
 Patients were included if they met the diagnostic criteria for a 
recurrent MDD according to the Structured Clinical Interview for 
DSM-IV  [37] , with a history of at least 3 depressive episodes. Pa-
tients had to be 18–65 years old and to have Internet access. Exclu-
sion criteria were: an acute suicide risk; a history of psychosis, bi-
polar disorder, or an organic brain disorder; a primary diagnosis 
of another DSM-IV axis I disorder; severe medical conditions; se-
vere cognitive impairment; illiteracy, and insufficient fluency in 
the German language. Patients were screened for eligibility by clin-
ical experts shortly after admission to inpatient treatment for their 
current acute depressive episode. After a complete description of 
the study had been provided to the subjects, written informed con-
sent was obtained.
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 Randomization 
 Patients were randomly assigned to 1 of the 3 study arms at a 
1: 1:1 allocation ratio by a centralized online procedure at hospital 
discharge. Randomization was stratified by the number of previ-
ous episodes (2–3, 4–7, or >7) and depression severity at the end 
of the index treatment (PSR: 1–2 or 3–4) using the Psychiatric Sta-
tus Rating (PSR) of the Longitudinal Interval Follow-Up Evalua-
tion (LIFE)  [38] . To enhance concealment, site was not used for 
stratification.
 Interventions 
 Treatment as Usual. All patients received the usual care recom-
mended by the German national practice guidelines for recurrent-
ly depressed patients, including maintenance antidepressant
medication and clinical management  [15] (online suppl. table ST1; 
see www.karger.com/doi/10.1159/000441951 for all online suppl. 
material). Patients provided the name and address of their TAU 
practitioner, who then was informed of the patient’s study partici-
pation. There were no restrictions on TAU treatments during this 
study.
 Supplemental to TAU, patients received proactive preparation 
for recurrence of depressive symptoms through an individual cri-
sis management plan (CMP) developed with the study site clinical 
expert shortly before randomization (see online suppl. table ST2 
for examples). All patients had access to the project website with 
general trial information and emergency contacts.
 The Internet-delivered augmentations (SUMMIT and SUM-
MIT-PERSON) aim to prolong euthymia by signaling upcoming 
crises, assisting the individual in personal crisis management, and 
facilitating early intervention if needed. Patients were offered a 
12-month participation in 1 of 2 versions of Internet-delivered 
augmentation of TAU. Both versions were delivered through a 
site-specific, encrypted, username- and password-protected web-
site.
 In both strategies, patients were accompanied via e-mail and/
or smartphone for 12 months after the inpatient index treatment, 
aiming to strengthen self-management skills and empowerment 
 [36] . Automated supportive monitoring based on the Brief Pa-
tient-Health Questionnaire (PHQ-9) [39] enabled patients to eval-
uate the course of their depression  [40] . Online provision of the 
CMP allowed proactive coping with any upcoming crisis. Further-
more, an Internet discussion forum provided peer support (online 
suppl. table ST2).
 Patients in the SUMMIT-PERSON group were additionally of-
fered (a) monthly consultation group chats with a clinical expert 
and (b) one-on-one chat consultations with a clinical expert when 
the patient’s monitoring signaled an upcoming crisis.
 Outcome Assessment and Blinding 
 Primary Outcomes . ‘Well’ and ‘unwell’ weeks over 24 months 
as determined by the PSR of the LIFE  [38] were the primary out-
comes. Weeks with PSR  ≤ 2 were considered well weeks (symp-
toms mostly absent) and weeks with PSR  ≥ 3 were unwell weeks (at 
least mild symptoms). The ratio of well to unwell weeks was esti-
mated by the ratio of transition rates from well to unwell, and back, 
which approximates the OR with respect to weeks between a well 
status and treatment conditions  [36] .
 Trained interviewers conducted LIFE interviews every 6 
months after randomization for a maximum of 24 months. The 
LIFE is a semi-structured interview and has proven to be a suitable 
measure for retrospective longitudinal assessments over periods of 
up to 24 months  [38] . According to the study plan, the last patient 
enrolled was followed up for 12 months. Patients were censored 
after their last interview if they were observed for less than 24 
months. LIFE interviews were conducted via a secured voice-over-
IP system to facilitate audio recording. Trained raters blinded to 
the study site and intervention group evaluated outcomes. Patients 
received a compensation of EUR 25 per interview.
 Adverse Events 
 AE included any unfavorable medical events independently of 
a possible causal relation to the intervention. Serious AE (SAE) 
were defined as any life-threatening event or new or prolonged 
hospitalization. SAE were reported to and reviewed by the data and 
safety monitoring board.
 Statistical Analysis 
 The trial biostatistician conducted statistical analyses using R 
software version 3.0.3. All analyses were intention to treat.
 This trial was powered assuming a 0.8 relative risk of transition 
from well to unwell and a 1.25 relative chance of transition from 
unwell to well for SUMMIT compared to TAU, as well as for SUM-
MIT-PERSON compared to SUMMIT. Transitions were formu-
lated as time-to-event models and analyzed by Cox proportional 
hazards regression models with multiple events per patient; a 
shared-frailty term was used for the patients  [41, 42] . Intervention 
(SUMMIT, SUMMIT-PERSON), site, age (linear), sex, number of 
previous depression episodes (linear), and level of depressive 
symptoms (PSR, linear) at the end of the index treatment were 
used as explanatory variables. The global hypothesis of any effect 
was tested (α = 5%, 2-tailed) via summing of the likelihood ratio 
test statistics for intervention in both the well and the unwell mod-
els and comparison with the 95th percentile of the central χ 2 dis-
tribution with 4 degrees of freedom. Sensitivity analyses were con-
ducted in the per protocol sample and under a best- and a worst-
case scenario for the imputation of missing data. The Wald 
method was used to estimate the p values and 95% CI of specific 
contrasts.
 Results 
 Patient Flow 
 Four hundred fifty-eight patients were screened for 
eligibility ( fig. 1 ), and 222 (48%) of these were excluded. 
Of the 236 eligible patients, 80 were randomized to TAU, 
77 to SUMMIT, and 79 to SUMMIT-PERSON. Eight par-
ticipants discontinued their study participation (TAU, 
n = 5; SUMMIT, n = 3), and 4 of these withdrew consent 
and requested deletion of their data (TAU, n = 2; SUM-
MIT, n = 2). This yielded an intention-to-treat sample of 
232 participants. Seventeen participants could not be in-
terviewed, and hence no PSR data were available on their 
symptom course during follow-up. One patient (TAU) 
was interviewed only once because his index treatment 
lasted 5.5 months.
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(n = 458)
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(n = 236)
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Allocated to
TAU + SUMMIT
(n = 77)
Analyzed
Intention to treat (n = 75)
Excluded from analysis (n = 2)
• Dropped out (consent withdrawn) (n = 2) 
Per protocol (n = 47)
Excluded from analysis (n = 30)
• Not per protocol (n = 28)
• Dropped out (consent withdrawn) (n = 2)
Completed 6-month LIFE (n = 69)
Lost to follow-up (n = 8)
• Could not be contacted (n = 6)
• Declined to participate (n = 1)
• Dropped out (consent withdrawn) (n = 1)
Completed 12-month LIFE (n = 67)
Regular end of study (n = 0)
Lost to follow-up (n = 2)
• Could not be contacted (n = 2)
Completed 24-month LIFE (n = 54)
Regular end of study (n = 7)
Lost to follow-up (n = 0)
Completed 18-month LIFE (n = 61)
Regular end of study (n = 3)
Lost to follow-up (n = 3)
• Could not be contacted (n = 2)
• Dropped out (consent withdrawn) (n = 1)
Allocated to
TAU + SUMMIT-PERSON
(n = 79)
Analyzed
Intention to treat (n = 79)
Excluded from analysis (n = 0)
Per protocol (n = 57)
Excluded from analysis (n = 22)
• Not per protocol (n = 22)
Completed 6-month LIFE (n = 75)
Lost to follow-up (n = 4)
• Could not be contacted (n = 4)
Completed 12-month LIFE (n = 69)
Regular end of study (n = 0)
Lost to follow-up (n = 6)
• Could not be contacted (n = 6)
Completed 24-month LIFE (n = 50)
Regular end of study (n = 12)
Lost to follow-up (n = 0)
Completed 18-month LIFE (n = 62)
Regular end of study (n = 3)
Lost to follow-up (n = 4)
• Could not be contacted (n = 4)
Allocated to TAU
(n = 80)
Analyzed
Intention to treat (n = 78)
Excluded from analysis (n = 2)
• Dropped out (consent withdrawn) (n = 2) 
Per protocol (n = 78)
Excluded from analysis (n = 2)
• Dropped out (consent withdrawn) (n = 2)
Completed 6-month LIFE (n = 72)
Lost to follow-up (n = 8)
• Could not be contacted (n = 6)
• Dropped out (consent withdrawn) (n = 2)
Completed 12-month LIFE (n = 69)
Regular end of study (n = 1)
Lost to follow-up (n = 2)
• Could not be contacted (n = 1)
• Declined to participate (n = 1)
Completed 24-month LIFE (n = 50)
Regular end of study (n = 10)
Lost to follow-up (n = 0)
Completed 18-month LIFE (n = 60)
Regular end of study (n = 4)
Lost to follow-up (n = 5)
• Could not be contacted (n = 3)
• Declined to participate (n = 2)
Excluded (n = 222)
• Did not meet the inclusion criteria (n = 82):
    Primary diagnosis not depression (n = 18)
    Less than 3 episodes (n = 29)
    No Internet access (n = 35)
• Declined to participate (n = 87)
• Other reasons/exclusion criteria (n = 53):
    Psychotic symptoms/bipolar (n = 19)
    Borderline personality disorder (n = 7)
    Severe medical condition (n = 1)
    Insufficient German (n = 7)
    Lack of basic computer skills (n = 11)
    Other reasons (n = 11)
 Fig. 1. CONSORT diagram. 
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 Sample 
 All patients were diagnosed with SCID-defined recur-
rent MDD. Half of the patients met the diagnostic crite-
ria for one or more other DSM-IV axis I diagnoses, of 
which anxiety disorders were the most prevalent (online 
suppl. table ST3). Forty-two patients met the criteria for 
one or more axis II personality disorders. Fifty-seven pa-
tients reported prior suicide attempts and 10 were sui-
cidal at the beginning of their index treatment. The cur-
rent index inpatient treatment lasted 68.4 days (SD 41.2), 
on average.
 On average, patients had experienced 5.6 (SD 3.7) life-
time depressive episodes prior to this study, and two 
thirds showed residual symptoms (PSR >2) upon clinical 
expert evaluation at hospital discharge (SUMMIT, 69%; 
SUMMIT-PERSON, 62%, and TAU, 63%). Half of the 
patients experienced a relapse/recurrence within the 
24-month observation period (SUMMIT, 51%; SUM-
MIT-PERSON, 51%, and TAU, 53%; further details are 
available in online suppl. table ST3).
 Therapists and Treatment Integrity 
 Patients in all 3 arms received TAU following German 
treatment guidelines  [15] . Almost all patients (99%) re-
ported having received continuous outpatient treatment 
(online suppl. table ST1). One third was rehospitalized at 
least once during follow-up. Nearly all patients continu-
ously took antidepressants, and about two thirds received 
additional psychotropic medication such as antipsychotics 
or mood stabilizers. Medical treatment did not differ 
across the 3 groups, with 1 exception: TAU-alone pa-
tients received additional psychotropic medication slight-
ly more often (TAU, 74%; SUMMIT, 65%, and SUMMIT-
PERSON, 55%).
 Uptake of the Internet-Delivered Augmentation 
Strategies 
 On average, patients completed two thirds of the 
monitoring assessments in both groups, i.e. SUMMIT 
(mean 68.9%, SD 32.8, median 84%) and SUMMIT-
PERSON (mean 68.7%, SD 34.6, median 84%), over the 
12-month intervention. The CMP was accessed on aver-
age 3.7 times (further utilization details are available in 
online suppl. table ST4). Of the patients allocated to 
SUMMIT-PERSON, 15 (19%) attended at least 1 month-
ly expert group chat. Due to the course of their symp-
toms, 57 patients were encouraged to consult the clinical 
expert in a one-on-one chat, which was utilized by 4 pa-
tients.
 Primary Outcome 
 Half of the patients (n = 121; 52%) experienced at least 
2 transitions of symptom status from well (PSR  ≤ 2) to 
unwell (PSR >2) and back, or from unwell to well and 
back, during the follow-up period. The global hypothesis 
predicted an accumulated gain of well weeks through de-
celerated transitions from well to unwell and accelerated 
transitions from unwell to well for both Internet-deliv-
ered strategies compared to TAU alone, and for SUM-
MIT-PERSON compared to SUMMIT. The test of this 
composed global hypothesis was not significant [χ 2 
(d.f. = 4) 5.29, p =  0.26].
 Exploration of specific contrasts at the primary end-
point indicated the efficacy of SUMMIT compared to 
TAU alone (OR 0.48; 95% CI 0.23–0.98; p = 0.04). This 
effect was composed of slower transitions from well to 
unwell (OR 0.69; 95% CI 0.44–1.09; p = 0.11) and faster 
transitions from unwell to well (OR 1.44; 95% CI 0.83–
2.50; p = 0.19; online suppl. table ST5). Comparison of 
SUMMIT-PERSON with TAU alone pointed in the same 
direction, but this did not reach statistical significance 
(OR 0.62; 95% CI 0.31–1.24; p = 0.18). No substantial 
 difference between SUMMIT and SUMMIT-PERSON 
emerged (OR 0.77; 95% CI 0.38–1.56; p = 0.47; online 
suppl. table ST5).
 For both Internet-delivered interventions, the effect 
on transition from unwell to well was strongest after the 
intervention, i.e. at the 12-month evaluation (SUMMIT-
PERSON vs. TAU: OR 1.90; 95% CI 1.06–3.41; p = 0.03; 
SUMMIT vs. TAU: OR 1.89; 95% CI 1.04–3.44; p = 0.04), 
and weakened until the 24-month evaluation (online 
 suppl. table ST5). The effect on transition from well to 
unwell peaked for SUMMIT at 20 months, i.e. 8 months 
after the intervention (OR 0.61; 95% CI 0.37–1.00; p = 
0.05), and weakened at the 24-month evaluation (online 
suppl. table ST5). 
 The accumulated gains are illustrated by the median 
proportions of well weeks: 52% in SUMMIT and 48% in 
SUMMIT-PERSON versus 31% in TAU alone.
 Adverse Events 
 One hundred sixty-nine AE were rated as serious ac-
cording to prespecified criteria (mostly rehospitalizations 
due to worsening depressive symptoms or suicidal ide-
ation). Events were equally distributed across the 3 study 
arms. Three patients had suicide attempts or committed 
serious self-injuries (SUMMIT, n = 2; TAU, n = 1). No 
fatal outcomes or deaths occurred during this trial. No 
participant was withdrawn from this study.
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 Discussion 
 This treatment augmentation trial yielded promising 
yet ambiguous findings. A fully automated version of the 
Internet-delivered depression management strategy SUM-
MIT proved efficacious compared to TAU alone. Contrary 
to the prediction, SUMMIT-PERSON showed no benefit 
compared to either SUMMIT or TAU. This led to failure 
to reject the composed global null hypothesis testing the 
overall difference between the 3 groups. The main addi-
tional feature of SUMMIT-PERSON compared to SUM-
MIT was the patient’s option to review their individual 
CMP together with a clinical expert in an online chat. Pa-
tients rarely used this option. Hence the additional benefit 
assumed in the power analysis proved unrealistic.
 As hypothesized, the gains of SUMMIT accumulated 
over decelerated transitions from well to unwell and ac-
celerated transitions from unwell to well. Together, the 
odds of unwell weeks were halved for SUMMIT com-
pared to TAU alone. This size corresponds to the aim of 
improvement on which the power analysis was based. As 
this study was powered for the accumulated effect, it 
lacked power to reliably estimate the separate effects of 
the 2 directions of the transitions. However, the data 
point to a preventive effect (transitions from well to un-
well) as well as to a crisis management effect (unwell to 
well) and invite further exploration. While the crisis man-
agement effect was strongest upon discontinuation of 
SUMMIT, the preventive effect peaked at 20 months, i.e. 
8 months after discontinuation. These differential time 
patterns might be due to the fact that only one third of the 
patients started with a well status, while two thirds of the 
patients started with an unwell status, and the median 
time to change to well was 44 weeks in SUMMIT (vs. 55 
weeks in TAU). SUMMIT-PERSON replicated these 
findings for the crisis management effect, which again 
was strongest upon discontinuation.
 This study has several implications. First, for most pa-
tients with 3 or more depressive episodes the chance of 
recovery is small  [18] . Therefore, an extension of well 
times is a highly relevant objective for mental health ser-
vices. On average, patients receiving TAU alone could ex-
pect only 16 well weeks per year. The novel Internet-de-
livered augmentations promise meaningful clinical im-
provements through an increase to 27 (SUMMIT) and 25 
(SUMMIT-PERSON) well weeks per year.
 Second, a stable symptom course was exceptional. Two 
thirds of the patients started follow-up within an unwell 
status, and two thirds of these changed at least once to a 
well status during the observation period; 3 quarters of 
these changed back to an unwell status. Almost 3 quarters 
of the patients who started the postinpatient period with a 
well status changed at least once to unwell, and almost all 
of them returned to well. Furthermore, the observed rates 
of relapse/recurrence corresponded to those reported in 
the literature for this patient group  [18–24] . This under-
scores the value of an adaptive strategy  [25, 26] such as 
SUMMIT that has the capability of halving the odds for 
unwell times by both decelerating transitions from well to 
unwell and accelerating transitions from unwell to well.
 Third, according to the literature, Internet-delivered 
interventions suffer from high attrition, which personal 
contact can reduce  [29, 35] . In our study, however, the 
dropout rate was low across all 3 arms (3%). Thus, the ad-
ditional personal-contact resources of SUMMIT-PER-
SON may not further augment under the conditions of 
the present study, where the Internet-delivered interven-
tion was integrated into well-established mental health 
services. Specifically, continuous contact with the TAU 
clinician might have reduced the wish to contact an ex-
pert online. This suggests a need to place these novel ser-
vices in the hands of TAU therapists to examine whether 
and how that may change utilization.
 This study has several strengths. It includes a large 
sample of patients with recurrent depression and a high 
risk of relapse due to at least 3 episodes and a lack of full 
remission at the end of their index inpatient treatment.
 This study aims beyond placebo beating. All patients 
received time-unlimited outpatient aftercare according 
to treatment guidelines (TAU), including antidepressant 
maintenance medication and clinical management. Thus, 
TAU represented a rather strong comparator, corre-
sponding to the study objective of improving mental 
health services.
 Augmentation of TAU with the novel Internet-deliv-
ered services provided after intense acute-phase treat-
ment can be understood as an individualized sequential 
strategy  [26, 27] . Reinforcement of feedback during well 
phases and provision of an individualized CMP at times 
when symptoms are exacerbated are responses to 
the changing needs of the individual patient. The in-
clusion criteria and in-hospital recruitment limit the 
generalizability of the findings. Fully reimbursed hos-
pital treatment – with an average duration of more than 
2 months – is common practice in the German health 
care system. However, the high comorbidity, long illness 
histories, and prevalence of suicidality in our sample in-
dicate that we may have selected sicker patients for this 
study through recruitment in hospitals. These specifics 
of the German health service system may make transla-
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tion to other countries with different health system con-
ditions an open question.
 In conclusion, the novel Internet-delivered service has 
the potential to reduce the lifelong burden of patients 
with recurrent depression. This clinical trial investigated 
a 12-month version of SUMMIT (and SUMMIT-PER-
SON) as a first step towards a lifelong individualized 
adaptive depression management strategy  [18, 26, 27] . 
The crisis management effect on transitions from unwell 
to well, as well as the preventive effect, faded after discon-
tinuation of the Internet-delivered services, which is a 
common observation in maintenance treatments  [22, 23] . 
This invites testing of an open-ended provision to in-
crease the durability of the effects. There is no financial 
reason for a time limit, because SUMMIT is fully auto-
mated. Most costs, such as for maintenance, are fixed. 
Variable costs emerge only through the introduction of 
the patient to the online system.
 We can only speculate about what helped the patients 
and presume that the Internet-delivered services enhance 
patients’ empowerment, their self-management skills, 
and particularly their capability for self-therapy  [27, 43] . 
Patients do not expect the new Internet-delivered inter-
vention to be a panacea (online suppl. table ST6). They 
learn to evaluate the course of their symptoms through 
supportive monitoring. They are encouraged to proac-
tively cope with an upcoming crisis with the support of 
their CMP. This may reduce feelings of helplessness and 
strengthen the patient’s understanding of being a partner 
of the TAU therapist. Ultimately, this might increase the 
patient’s willingness to share responsibility for their de-
pression management and thus to get more from it.
 The utilization data demonstrated that both Internet-
delivered management strategies were well accepted by 
the study participants. Unfortunately, we did not have the 
resources to systematically collect information on the 
view of the more than 200 TAU therapists involved in this 
study. However, none of them objected to their patients’ 
participation in this study, which can be read as implicit 
acceptance. Therapists may be interested in sharing with 
their patients the continuous information provided 
through supportive monitoring for a better match be-
tween the care provided and the – changing – needs of the 
individual patient  [25] . Together with the clinical benefits 
of the new services, this raises the hope that TAU thera-
pists may be persuaded to join their patients in using this 
new individualized adaptive strategy in a future transla-
tional research project.
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